Vaderis Therapeutics

News

Our round-up of venture capital financings in biotech this week features Vaderis, Aureka, Epicrispr, Infinimmune, and Boulevard Bio.

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.